Systemic Therapy With or Without Local Consolidative Therapy in Treating Patients With Oligometastatic Solid Tumor

Inclusion Criteria: * Oligometastatic solid tumors (see protocol for relevant disease sites) patients (=\< 5 metastatic lesions at the time of study entry) * Candidate for definitive local therapy to all sites of active disease per the discretion of the treating physicians * No more than 4 prior lines of systemic therapy administered to treat metastatic disease * Pathologically confirmed diagnosis of cancer as specified in protocol * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Absolute neutrophil count (ANC) \>= 500/mcL (performed within 6 weeks prior to study enrollment) * Platelets \>= 25,000/mcL (performed within 6 weeks prior to study enrollment) * Hemoglobin \>=7 g/dL (performed within 6 weeks prior to study enrollment) * Serum total bilirubin =\< 1.5 mg/dl (except for subjects with Gilbert syndrome, who may have total bilirubin \< 3.0 mg/dl) OR direct bilirubin =\< upper limit normal (ULN) for subjects with total bilirubin levels \> 1.5 mg/dl (performed within 6 weeks prior to study enrollment) * Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) =\< 3 X ULN OR =\< 5 X ULN for subjects with liver metastases (performed within 6 weeks prior to study enrollment) Exclusion Criteria: * Has a diagnosis of active scleroderma, lupus, or other rheumatologic disease which in the opinion of the treating radiation oncologist precludes safe radiation t…